login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

CONNECT II clinical trial completes enrolment


Wednesday, 13 Jun 2012 09:43
Ocelot
Ocelot

Avinger has announced that it has successfully completed enrolment in its CONNECT II global clinical trial. A study focused on treatment of peripheral artery disease. CONNECT II is a prospective, multicentre, non-randomised global clinical study that evaluated 100 peripheral artery disease patients with femoropopliteal chronic total occlusion lesions at 15 hospital and clinic sites, including two in the European Union.


As part of the trial, an independent group of physicians are reviewing the angiographic results to determine Ocelot’s safety and efficacy. According to Avinger (manufacturer of this device), it is the first-ever interventional chronic total occlusion (CTO) crossing catheter to use real-time intravascular imaging technology called optical coherence tomography, or OCT. It allows physicians to cross, see and navigate inside totally blocked arteries in the legs of patients suffering from peripheral artery disease.

“We are pleased to reach this significant milestone ahead of schedule and already see promising preliminary data collected,” said John B Simpson, CEO and founder, Avinger. “We appreciate the patient participation and dedicated efforts of our employees, physician investigators and their research staff. Together, we are now one step closer to bringing the Ocelot technology to patients who need it most.”


The company will present CONNECT II aggregate results at the VIVA conference (Las Vegas, USA, 9–12 October 2012), file a 510K with the FDA later this summer, and expects to receive 510K clearance in late 2012. In order to ensure Ocelot is available for use at US CONNECT II sites during the 510K review period, Avinger has also requested FDA approval of an additional 125 patients to be enrolled and treated in a continued access cohort.


“I believe the results from this trial will have a major impact on how physicians treat patients with severe peripheral artery disease. We are pleased that a request for continued access has been submitted. It means the Heart Hospital may be able to continue treating patients with Ocelot in order to quickly improve their mobility and return to a healthier quality of life,” said Matthew Selmon, Heart Hospital Austin, Texas and co-principal investigator for the trial.


“This is the first-ever interventional device that allows us to drill through the totally blocked arteries in the legs while using an integrated camera to see it from the inside,” said Arne Schwindt, St Franziskus Hospital, Muenster, Germany and co-principal investigator in the trial. “This is a major advance for patients suffering from peripheral artery disease, and holds the potential to postpone or entirely avoid surgical bypasses and amputations.”


Ocelot received CE mark in 2011.




Add New Comment

Most popular


OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression
Wednesday, 18 Jun 2014
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients ... OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression

Medtronic to acquire Covidien for US$42.9 billion in cash and stock
Monday, 16 Jun 2014
The acquistion creates a medical technology and services company with a comprehensive product portfolio and broad global reach. Medtronic to acquire Covidien for US$42.9 billion in cash and stock

FDA advisory panel unanimously recommends approval for Lutonix DCB
Friday, 13 Jun 2014
Lutonix DCB is one step closer to becoming the first US FDA-approved drug-coated balloon for the treatment of patients with femoropopliteal occlusive disease. FDA advisory panel unanimously recommends approval for Lutonix DCB

Features


The 11th Scientific Meeting of the Chinese Society of Interventional Radiology successfully held in Changsha
Tuesday, 08 Jul 2014
The 11th Scientific Meeting of the Chinese Society of Interventional Radiology (2014 CSIR) was held from 11–15 June 2014 in Changsha, Hunan Province, China. The Chinese Society of Interventional R... The 11th Scientific Meeting of the Chinese Society of Interventional Radiology successfully held in Changsha

Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy
Tuesday, 08 Jul 2014
Unintended non-target delivery of embolic agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or ... Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Profiles


Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

James B Spies
Friday, 16 May 2014
The evolution of embolization over the past decade has been remarkable and it has fundamentally ... James B Spies

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions